Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D (2021) Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 7:47

Article  PubMed  Google Scholar 

Bai B, Zeng G, Chen R, Ai Y, Qiang H (2021) Upregulation of iASPP ameliorates hypoxia/reoxygenation-induced apoptosis and oxidative stress in cardiomyocytes by upregulating Nrf2 signaling. J Biochem Mol Toxicol 35:e22686

Article  CAS  PubMed  Google Scholar 

Bergamaschi D, Samuels Y, O’Neil NJ, Trigiante G, Crook T, Hsieh JK, O’Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE, Lu X (2003) iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33:162–167

Article  CAS  PubMed  Google Scholar 

Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38:1133–1141

Article  CAS  PubMed  Google Scholar 

Chan KK, Wong OG, Wong ES, Chan KK, Ip PP, Tse KY, Cheung AN (2018) Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma. Int J Cancer 143:1456–1469

Article  CAS  PubMed  Google Scholar 

Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the astrocyte. Proc Natl Acad Sci U S A 106:2933–2938

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cuadrado A (2022) Brain-protective mechanisms of transcription factor NRF2: toward a common strategy for neurodegenerative diseases. Annu Rev Pharmacol Toxicol 62:255–277

Article  CAS  PubMed  Google Scholar 

Ge W, Zhao K, Wang X, Li H, Yu M, He M, Xue X, Zhu Y, Zhang C, Cheng Y, Jiang S, Hu Y (2017) iASPP is an antioxidative factor and drives Cancer Growth and Drug Resistance by competing with Nrf2 for Keap1 binding. Cancer Cell 32:561–573 e566

Article  CAS  PubMed  Google Scholar 

Hayes JD, Dinkova-Kostova AT (2017) Oncogene-stimulated congestion at the KEAP1 stress signaling hub allows bypass of NRF2 and induction of NRF2-Target genes that promote Tumor Survival. Cancer Cell 32:539–541

Article  CAS  PubMed  Google Scholar 

Huang M, Bargues-Carot A, Riaz Z, Wickham H, Zenitsky G, Jin H, Anantharam V, Kanthasamy A, Kanthasamy AG (2022) Impact of environmental risk factors on mitochondrial dysfunction, Neuroinflammation, protein misfolding, and oxidative stress in the etiopathogenesis of Parkinson’s Disease. Int J Mol Sci 23:10808

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inose Y, Izumi Y, Takada-Takatori Y, Akaike A, Koyama Y, Kaneko S, Kume T (2020) Protective effects of Nrf2-ARE activator on dopaminergic neuronal loss in Parkinson disease model mice: possible involvement of heme oxygenase-1. Neurosci Lett 736:135268

Article  CAS  PubMed  Google Scholar 

Jakel RJ, Townsend JA, Kraft AD, Johnson JA (2007) Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 1144:192–201

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Cao Y, Xiao J, Shang J, Tan Q, Ping F, Huang W, Wu F, Zhang H, Zhang X (2020a) Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury. Cell Death Differ 27:2635–2650

Li H, Zhang W, Zhao K, Zhao D, Zheng S, Hu Y (2020b) A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells. J Biol Chem 295:4049–4063

Liu X, Li F, Zhao S, Luo Y, Kang J, Zhao H, Yan F, Li S, Ji X (2013) MicroRNA-124-mediated regulation of inhibitory member of apoptosis-stimulating protein of p53 family in experimental stroke. Stroke 44:1973–1980

Article  CAS  PubMed  Google Scholar 

Liu X, Wen S, Zhao S, Yan F, Zhao S, Wu D, Ji X (2018) Mild therapeutic hypothermia protects the Brain from Ischemia/Reperfusion Injury through Upregulation of iASPP. Aging Dis 9:401–411

Article  PubMed  PubMed Central  Google Scholar 

Liu S, Pi J, Zhang Q (2022a) Signal amplification in the KEAP1-NRF2-ARE antioxidant response pathway. Redox Biol 54:102389

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu H, Zhao D, Li H, Zhang W, Lin Q, Wang X, Zheng S, Zhang L, Li L, Hu S, Hu Y (2022b) Blocking iASPP/Nrf2/M-CSF axis improves anti-cancer effect of chemotherapy-induced senescence by attenuating M2 polarization. Cell Death Dis 13:166

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masaki Y, Izumi Y, Matsumura A, Akaike A, Kume T (2017) Protective effect of Nrf2-ARE activator isolated from green perilla leaves on dopaminergic neuronal loss in a Parkinson’s disease model. Eur J Pharmacol 798:26–34

Article  CAS  PubMed  Google Scholar 

Niu Y, Zhang J, Dong M (2021) Nrf2 as a potential target for Parkinson’s disease therapy. J Mol Med (Berl) 99:917–931

Article  CAS  PubMed  Google Scholar 

Notari M, Hu Y, Koch S, Lu M, Ratnayaka I, Zhong S, Baer C, Pagotto A, Goldin R, Salter V, Candi E, Melino G, Lu X (2011) Inhibitor of apoptosis-stimulating protein of p53 (iASPP) prevents senescence and is required for epithelial stratification. Proc Natl Acad Sci U S A 108:16645–16650

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliveira LMA, Gasser T, Edwards R, Zweckstetter M, Melki R, Stefanis L, Lashuel HA, Sulzer D, Vekrellis K, Halliday GM, Tomlinson JJ, Schlossmacher M, Jensen PH, Schulze-Hentrich J, Riess O, Hirst WD, El-Agnaf O, Mollenhauer B, Lansbury P, Outeiro TF (2021) Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease. NPJ Parkinsons Dis 7:65

Article  PubMed  PubMed Central  Google Scholar 

Ulasov AV, Rosenkranz AA, Georgiev GP, Sobolev AS (2022) Nrf2/Keap1/ARE signaling: towards specific regulation. Life Sci 291:120111

Article  CAS  PubMed  Google Scholar 

Wang CY, Zhang Q, Xun Z, Yuan L, Li R, Li X, Tian SY, Xin N, Xu Y (2020) Increases of iASPP-Keap1 interaction mediated by syringin enhance synaptic plasticity and rescue cognitive impairments via stabilizing Nrf2 in Alzheimer’s models. Redox Biol 36:101672

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Gao L, Chen J, Li Q, Huo L, Wang Y, Wang H, Du J (2021) Pharmacological modulation of Nrf2/HO-1 signaling pathway as a therapeutic target of Parkinson’s Disease. Front Pharmacol 12:757161

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wen L, Yang S, Li P, Chen R, Wang Q, Kaspo B, Fan H, Hu J (2020) iASPP-Mediated ROS inhibition drives 5-Fu Resistance Dependent on Nrf2 Antioxidative Signaling Pathway in gastric adenocarcinoma. Dig Dis Sci 65:2873–2883

Article  CAS  PubMed  Google Scholar 

Wilson AM, Chiodo VA, Boye SL, Brecha NC, Hauswirth WW, Di Polo A (2014) Inhibitor of apoptosis-stimulating protein of p53 (iASPP) is required for neuronal survival after axonal injury. PLoS One 9:e94175

Article  PubMed  PubMed Central  Google Scholar 

Xue Y, Han H, Wu L, Pan B, Dong B, Yin CC, Tian Z, Liu X, Yang Y, Zhang H, Chen Y, Chen J (2017) iASPP facilitates tumor growth by promoting mTOR-dependent autophagy in human non-small-cell lung cancer. Cell Death Dis 8:e3150

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yagudin T, Zhao Y, Gao H, Zhang Y, Yang Y, Zhang X, Ma W, Daba TM, Ishmetov V, Kang K, Yang B, Pan Z (2021) iASPP protects the heart from ischemia injury by inhibiting p53 expression and cardiomyocyte apoptosis. Acta Biochim Biophys Sin (Shanghai) 53:102–111

Article  CAS  PubMed  Google Scholar 

Yi H, Huang Y, Yang F, Liu W, He S, Hu X (2017) MicroRNA-182 aggravates cerebral ischemia injury by targeting inhibitory member of the ASPP family (iASPP). Arch Biochem Biophys 620:52–58

Article